Home›Clinical trials›Pennsylvania

GLP-1 clinical trials in Pennsylvania: 32 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

32 GLP-1 clinical trials are recruiting at 50 sites in 19 cities across Pennsylvania. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Pennsylvania

  1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    2 sites in Pennsylvania

  2. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06857942.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    1 site in Pennsylvania

    • Dermatology Associates of Plymouth Meeting, Plymouth Meeting

  3. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    5 sites in Pennsylvania

  4. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    4 sites in Pennsylvania

  5. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    4 sites in Pennsylvania

    • Heritage Valley Medical Group, Beaver. 833-602-2368
    • Preferred Primary Care Physicians, Pittsburgh. 833-602-2368
    • Preferred Primary Care Physicians-Pittsburgh-63932, Pittsburgh. 833-602-2368
    • Preferred Primary Care Physicians - Matthew Drive, Uniontown. 833-602-2368

  6. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    3 sites in Pennsylvania

    • US Digestive Health - Flourtown, Flourtown. 215-664-4362
    • Penn Medicine: University of Pennsylvania Health System, Philadelphia
    • US Digestive Health - Wyomissing, Wyomissing. 610-374-4401

  7. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    3 sites in Pennsylvania

    • Heritage Valley Medical Group, Beaver
    • Hatboro Med Associates, Hatboro
    • Northeast Endocrine Metabolic Associates, Philadelphia

  8. A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07202884.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    2 sites in Pennsylvania

    • OB/GYN Associates of Erie, Erie
    • Clinical Research of Philadelphia, Philadelphia. 215-676-6696

  9. Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. Run by VA Office of Research and Development. Registry number NCT07218354.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    2 sites in Pennsylvania

    • Corporal Michael J. Crescenz VA Medical Center, Philadelphia. 2158235800
    • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia. (215) 823-5894

  10. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    2 sites in Pennsylvania

    • Research Site, Feasterville-Trevose
    • Research Site, Philadelphia

  11. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in Pennsylvania

    • UPMC Children's Hospital of Pittsburgh, Pittsburgh. 412-692-6935

  12. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672939.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    1 site in Pennsylvania

    • Childrens Hospital of Pittsburgh, Pittsburgh

  13. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in Pennsylvania

    • Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia. 215-955-8900

  14. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937099.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    1 site in Pennsylvania

    • Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia. 215-955-8900

  15. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07153471.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in Pennsylvania

    • University Orthopedics Center, Altoona

  16. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07223593.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    1 site in Pennsylvania

  17. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07253285.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    1 site in Pennsylvania

    • UPMC Child Hosp-Pittsburgh, Pittsburgh

  18. A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Run by Amgen. Registry number NCT07575399.

    A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    1 site in Pennsylvania

    • Altoona Center for Clinical Research, Duncansville

  19. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07770841.

    A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

    Who can join. Adults 18+, are overweight, BMI 27+.

    1 site in Pennsylvania

    • UPA Ctr Weight and Eating Dis, Philadelphia

  20. Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

    Phase 2. Run by Dan Zandberg. Registry number NCT04114136.

    A study of nivolumab or pembrolizumab in people with melanoma.

    Who can join. Adults 18+, have melanoma.

    1 site in Pennsylvania

The other 12 studies recruiting in Pennsylvania

  1. GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

    Phase 2. Run by University of Pennsylvania. Registry number NCT04731272.

    A study testing whether a GLP-1 medicine, dulaglutide, can help people with cystic fibrosis lower blood sugar.

    Who can join. Adults 18+, have cystic fibrosis, BMI 19+.

    1 site in Pennsylvania

  2. GLP-1R Agonist Treatment for Opioid Use Disorder

    Phase 2. Run by Milton S. Hershey Medical Center. Registry number NCT06548490.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18 to 75, have opioid use disorder, BMI 18+.

    1 site in Pennsylvania

  3. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06897475.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    1 site in Pennsylvania

  4. Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

    Phase 2. Run by Alaa Sada. Registry number NCT07573163.

    A study of a GLP-1 and GIP medicine, tirzepatide, in people with mild autonomous cortisol secretion (MACS).

    Who can join. Adults 18+, have mild autonomous cortisol secretion (MACS), BMI 27+.

    1 site in Pennsylvania

    • University of Pittsburgh Medical Center, Pittsburgh

  5. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07639021.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in Pennsylvania

    • UPA Ctr Weight and Eating Dis, Philadelphia

  6. A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07668388.

    A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    1 site in Pennsylvania

    • Preferred Primary Care Physicians, Inc., Uniontown

  7. Pharmacogenetics of Response to GLP1R Agonists

    Phase 1. Run by University of Maryland, Baltimore. Registry number NCT05071898.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18 to 89, have obesity, BMI 27+.

    1 site in Pennsylvania

  8. Feasibility of Semaglutide in Advanced Lung Disease

    Phase 1. Run by University of Pennsylvania. Registry number NCT05746039.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with interstitial lung disease lose weight.

    Who can join. Adults 18 to 80, have obesity, BMI 30+.

    1 site in Pennsylvania

    • University of Pennsylvania Perelman School of Medicine, Philadelphia

  9. Beta-cell Response to Incretin Hormones in Cystic Fibrosis

    Run by University of Pennsylvania. Registry number NCT01851694.

    A study in people with cystic fibrosis.

    Who can join. Adults 18+, have cystic fibrosis.

    1 site in Pennsylvania

    • Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia. 215-746-2081

  10. Identifying Changes in Food Behaviors Associated With Beginning GLP-1 Medication

    Run by Penn State University. Registry number NCT06843512.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 18+, BMI 25+.

    1 site in Pennsylvania

    • Health, Ingestive Behavior, and Technology Laboratory of Pennsylvania State University, State College. 425-499-8049

  11. Transformative Research in Diabetic Nephropathy 2.0

    Run by University of Pennsylvania. Registry number NCT07444203.

    A study testing whether a study medicine, Sodium-glucose cotransporter 2 inhibitors (SGLT2i), can help people with diabetic kidney disease protect their kidneys.

    Who can join. Adults 18+, have diabetic kidney disease.

    1 site in Pennsylvania

    • Penn Presbyterian Medical Center, Philadelphia. 2673030158

  12. The Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesity Medication

    Run by University of Pittsburgh. Registry number NCT07652333.

    A study in adults starting a GLP-1 medicine on their own prescription.

    Who can join. Adults 18+, have obesity, BMI 27+.

    1 site in Pennsylvania

    • Physical Activity Research Center, University of Pittsburgh, Pittsburgh. 515-817-4601

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.